A key innovation in this area has been the development of immune-mobilizing monoclonal TCRs against cancer (ImmTACs), which combine an engineered, high-affinity TCR specific for peptide–MHC complexes with an anti-CD3 scFv to redirect T-cell activity toward tumor cells. The gene discussed is HLA-C; the disease is neoplasm.